Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Phase 1b Dose Escalation Study of Sozinibercept Inhibition of Vascular Endothelial Growth Factors C and D With Aflibercept for Diabetic Macular Edema.
Journal: Translational vision science & technology
Published: December 19, 2024
Phase I Study of the Anti-interleukin 33 Fragment Antigen-Binding Region RO7303359 in Geographic Atrophy Secondary to Age-Related Macular Degeneration.
Journal: Ophthalmology science
Published: August 28, 2024
Safety and Tolerability of Suprachoroidal Axitinib Injectable Suspension, for Neovascular Age-related Macular Degeneration; Phase I/IIa Open-Label, Dose-Escalation Trial.
Journal: Ophthalmology science
Published: January 05, 2024
Private Equity: A Punctuated Equilibrium in Retina.
Journal: Journal of vitreoretinal diseases
Published: November 06, 2023
Randomized Trial of Biosimilar XSB-001 versus Reference Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration.
Journal: Ophthalmology. Retina
Published: April 07, 2023
Private equity ownership of ophthalmology practices: how does it impact clinical research?
Journal: Current opinion in ophthalmology
Published: August 02, 2022
Brolucizumab-associated intraocular inflammation in eyes without retinal vasculitis.
Journal: Journal of vitreoretinal diseases
Published: October 04, 2021
Occlusive Retinal Vasculitis Following Intravitreal Brolucizumab.
Journal: Journal of vitreoretinal diseases
Published: August 14, 2020
C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.
Journal: Ophthalmology
Published: May 11, 2020
Phase 1 Study of OPT-302 Inhibition of Vascular Endothelial Growth Factors C and D for Neovascular Age-Related Macular Degeneration.
Journal: Ophthalmology. Retina
Published: June 27, 2019
Last Updated: 09/26/2026